From A Very Different Angle: Abbott Laboratories (ABT), The TJX Companies Inc. (TJX)

You should consider shares of Abbott Laboratories (NYSE:ABT) and The TJX Companies Inc. (NYSE:TJX) if you are looking for a great stocks to invest in. Starting with the ABT shares, which traded at $87.38 at the close of the recent session, gaining 1.91%. On Wednesday, the company’s shares shed $1.64 from its value which represented in intraday trading. The stock is now 0.60% higher in year-to-date (YTD) trading. ABT’s intraday high was $87.85 while its lowest price touched $86.11. The stock’s 52-week high price is $89.24, which means the current price is at -2.08%. In terms of trading activity, the daily trading volume rose to 5272892 against 200-day average trading volume of 4,862,903 shares.

What are analyst forecasts for Abbott Laboratories (NYSE:ABT)?

At a consensus rating of 4.64, ABT is trending as a streaking Strong Buy, as it has been the case a month ago when 12 analysts called it a Strong Buy. Two months ago, 13 analysts recommended, on average, that ABT stock is a Strong Buy. The Healthcare company’s shares’ overall bullish trend saw it close lower on Wednesday compared to its opening price of $86.11 on the day.

Forecasts for Abbott Laboratories (NYSE:ABT) give the stock a fair value for the growth of 8.02% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $95.00, which means the price per share could rise by nearly $7.62. The price range target is between a low of $90.00 and a high of $102.00. The stock would need to gain by about $14.33 to hit the estimated high or 0.78% from its 12-month low.

The consensus among 19 analysts is that it is a good time for one to Overweight in the Abbott Laboratories. 13 analysts rate ABT as a Buy, with 0 of 19 analysts rate it as a Sell. 2 have valued the stock as Overweight and 3 have recommended that investors Hold.

Abbott Laboratories (NYSE:ABT) Upgrades and Downgrades

In terms of rating changes, Guggenheim on January 02, 2020, Downgrade Abbott Laboratories (ABT) at Neutral. Analysts at BofA/Merrill have assigned a Buy rating for the stock in their research note on June 13, 2019 with an estimated price target of $90. Moreover, BofA/Merrill analysts issued a rating of Buy for the stock on February 07, 2019, giving it a price target of $81 for the next 12 months. On January 02, 2019, the stock earned a Sell rating due to an analyst call from Citigroup, while analysts from Goldman on November 30, 2018 suggested that the stock is Buy.

The TJX Companies Inc. (NYSE:TJX) adds -$0.92 on Wednesday

The TJX stock has risen 1.21% year-to-date and is currently trading at $61.80, which is -1.95% below its 52-week high. The company shares lost -1.47% on the day and have risen nearly 32.47% off a low hit. At current levels, The TJX Companies Inc. has a valuation of about $40.64B. As of 01/15/20, this stock has fallen -0.19% during the week and closed at $62.72 in the previous session. However, recent The TJX Companies Inc. stock performance shows that TJX shares are 2.37% up over the last month, and 5.68% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $0.68, with the trailing 12-month share earnings at $2.54. The ratio is expected to be up by 8.20% for the current year 2019 and 8.70% for next year. Over the next 5-year period, earnings per share will be 8.60%. But will the TJX stock surprise in the current quarter results, where the $0.68 actual EPS reported on 10/30/2019 surprised by 3.00% or was higher by $0.02 from the estimated $0.66.

Sales Growth to climb 6.20% for the year

How well will The TJX Companies Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $11.74B and $11.94B in current quarter sales. The consensus estimated for the current quarter is $11.83B from sales. Forecasts for this fiscal year are between $41.25B and $41.45B and the consensus estimate for sales is at $41.34B. TJX has its next quarter sales estimates at between $9.71B and $9.95B, with the quarter-over-quarter growth estimates at -5.90% and the annual growth forecast for the year at 6.20%.

Who owns shares in The TJX Companies Inc. (TJX)?

Let’s briefly focus on the share ownership of the The TJX Companies Inc. (NYSE:TJX) stock, where we find that 93.18% of shares are held by institutions. Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 98.22 million shares or 8.16% of shares outstanding. Blackrock Inc. and Wellington Management Company, LLP held 93.91 million and 65.39 million representing 7.81% and 5.43% respectively at the close of the last trading session. As of Sep 29, 2019, State Street Corporation accounted for 58.23 million shares at over 3.25 billion. This represented 4.84% of shares outstanding. FMR, LLC held 51.23 million shares at over 2.86 billion representing 4.26% of shares outstanding.

TJX Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at The TJX Companies Inc. (TJX), a total of 201558 shares have been sold by insiders over the last 6 months while 329020 shares were added in the same time span. On 11/26/2019, President & Chief Executive Officer by the name Herrman Ernie L sold 127296.0 shares worth $7.7 million at the price of $60.38 per share. Filings also show that Meyrowitz Carol M sold a total of 116640.0 shares on 3/13/2019 valued at $6.1 million. Since the last insider activity, the company’s share price has climbed 17.76%.